Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

Lauren Greenberg; Lene Ryom; Elzbieta Bakowska; Ferdinand Wit; Heiner C. Bucher; Dominique L. Braun; Andrew Phillips; Caroline Sabin; Antonella d’Arminio Monforte; Robert Zangerle; Colette Smith; Stéphane De Wit; Fabrice Bonnet; Christian Pradier; Cristina Mussini; Camilla Muccini; Jörg J. Vehreschild; Jennifer Hoy; Veronica Svedhem; Jose M. Miró; Jan Christian Wasmuth; Peter Reiss; Josep M. Llibre; Nikoloz Chkhartishvili; Christoph Stephan; Camilla I. Hatleberg; Bastian Neesgaard; Lars Peters; Nadine Jaschinski; Nikos Dedes; Elena Kuzovatova; Marc Van Der Valk; Marianna Menozzi; Clara Lehmann; Kathy Petoumenos; Harmony Garges; Jim Rooney; Lital Young; Jens D. Lundgren; Loveleen Bansi-Matharu; Amanda Mocroft; on behalf of the RESPOND and D:A:D Study Groups

doi:10.3390/cancers15143640

Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

Lauren Greenberg, Lene Ryom, Elzbieta Bakowska, Ferdinand Wit, Heiner C. Bucher, Dominique L. Braun, Andrew Phillips, Caroline Sabin, Antonella d’Arminio Monforte, Robert Zangerle, Colette Smith, Stéphane De Wit, Fabrice Bonnet, Christian Pradier, Cristina Mussini, Camilla Muccini, Jörg J. Vehreschild, Jennifer Hoy, Veronica Svedhem, Jose M. MiróJan Christian Wasmuth, Peter Reiss, Josep M. Llibre, Nikoloz Chkhartishvili, Christoph Stephan, Camilla I. Hatleberg, Bastian Neesgaard, Lars Peters, Nadine Jaschinski, Nikos Dedes, Elena Kuzovatova, Marc Van Der Valk, Marianna Menozzi, Clara Lehmann, Kathy Petoumenos, Harmony Garges, Jim Rooney, Lital Young, Jens D. Lundgren, Loveleen Bansi-Matharu, Amanda Mocroft, on behalf of the RESPOND and D:A:D Study Groups

Infectious Diseases

Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Abstract

Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.

Original language	English
Article number	3640
Number of pages	25
Journal	Cancers
Volume	15
Issue number	14
DOIs	https://doi.org/10.3390/cancers15143640
Publication status	Published - Jul 2023

Keywords

AIDS defining cancer
body mass index
HIV
incidence
infection
non-AIDS defining cancer
smoking
trends

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers15143640Licence: CC BY

Cite this

Greenberg, L., Ryom, L., Bakowska, E., Wit, F., Bucher, H. C., Braun, D. L., Phillips, A., Sabin, C., d’Arminio Monforte, A., Zangerle, R., Smith, C., De Wit, S., Bonnet, F., Pradier, C., Mussini, C., Muccini, C., Vehreschild, J. J., Hoy, J., Svedhem, V., ... on behalf of the RESPOND and D:A:D Study Groups (2023). Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV. Cancers, 15(14), Article 3640. https://doi.org/10.3390/cancers15143640

@article{e7b177da0d064cb5aa1b303c93aa859c,

title = "Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV",

abstract = "Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-na{\"i}ve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.",

keywords = "AIDS defining cancer, body mass index, HIV, incidence, infection, non-AIDS defining cancer, smoking, trends",

author = "Lauren Greenberg and Lene Ryom and Elzbieta Bakowska and Ferdinand Wit and Bucher, {Heiner C.} and Braun, {Dominique L.} and Andrew Phillips and Caroline Sabin and {d{\textquoteright}Arminio Monforte}, Antonella and Robert Zangerle and Colette Smith and {De Wit}, St{\'e}phane and Fabrice Bonnet and Christian Pradier and Cristina Mussini and Camilla Muccini and Vehreschild, {J{\"o}rg J.} and Jennifer Hoy and Veronica Svedhem and Mir{\'o}, {Jose M.} and Wasmuth, {Jan Christian} and Peter Reiss and Llibre, {Josep M.} and Nikoloz Chkhartishvili and Christoph Stephan and Hatleberg, {Camilla I.} and Bastian Neesgaard and Lars Peters and Nadine Jaschinski and Nikos Dedes and Elena Kuzovatova and {Van Der Valk}, Marc and Marianna Menozzi and Clara Lehmann and Kathy Petoumenos and Harmony Garges and Jim Rooney and Lital Young and Lundgren, {Jens D.} and Loveleen Bansi-Matharu and Amanda Mocroft and {on behalf of the RESPOND and D:A:D Study Groups}",

note = "Funding Information: J.M.M. has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work. C.L. has received honoraria for speaking at educational events or consulting from BioNTech, Pfizer, Astra Zeneca, MSD, Novartis, Gilead, Janssen and ViiV. J.R. is an employee and stockholder of Gilead Sciences. A.M. has received honoraria, travel support and lecture fees from ViiV and Gilead, and honoraria from Eiland and Bonnin, all outside the submitted work. Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = jul,

doi = "10.3390/cancers15143640",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI AG",

number = "14",

}

Greenberg, L, Ryom, L, Bakowska, E, Wit, F, Bucher, HC, Braun, DL, Phillips, A, Sabin, C, d’Arminio Monforte, A, Zangerle, R, Smith, C, De Wit, S, Bonnet, F, Pradier, C, Mussini, C, Muccini, C, Vehreschild, JJ, Hoy, J, Svedhem, V, Miró, JM, Wasmuth, JC, Reiss, P, Llibre, JM, Chkhartishvili, N, Stephan, C, Hatleberg, CI, Neesgaard, B, Peters, L, Jaschinski, N, Dedes, N, Kuzovatova, E, Van Der Valk, M, Menozzi, M, Lehmann, C, Petoumenos, K, Garges, H, Rooney, J, Young, L, Lundgren, JD, Bansi-Matharu, L, Mocroft, A & on behalf of the RESPOND and D:A:D Study Groups 2023, 'Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV', Cancers, vol. 15, no. 14, 3640. https://doi.org/10.3390/cancers15143640

TY - JOUR

T1 - Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

AU - Greenberg, Lauren

AU - Ryom, Lene

AU - Bakowska, Elzbieta

AU - Wit, Ferdinand

AU - Bucher, Heiner C.

AU - Braun, Dominique L.

AU - Phillips, Andrew

AU - Sabin, Caroline

AU - d’Arminio Monforte, Antonella

AU - Zangerle, Robert

AU - Smith, Colette

AU - De Wit, Stéphane

AU - Bonnet, Fabrice

AU - Pradier, Christian

AU - Mussini, Cristina

AU - Muccini, Camilla

AU - Vehreschild, Jörg J.

AU - Hoy, Jennifer

AU - Svedhem, Veronica

AU - Miró, Jose M.

AU - Wasmuth, Jan Christian

AU - Reiss, Peter

AU - Llibre, Josep M.

AU - Chkhartishvili, Nikoloz

AU - Stephan, Christoph

AU - Hatleberg, Camilla I.

AU - Neesgaard, Bastian

AU - Peters, Lars

AU - Jaschinski, Nadine

AU - Dedes, Nikos

AU - Kuzovatova, Elena

AU - Van Der Valk, Marc

AU - Menozzi, Marianna

AU - Lehmann, Clara

AU - Petoumenos, Kathy

AU - Garges, Harmony

AU - Rooney, Jim

AU - Young, Lital

AU - Lundgren, Jens D.

AU - Bansi-Matharu, Loveleen

AU - Mocroft, Amanda

AU - on behalf of the RESPOND and D:A:D Study Groups

N1 - Funding Information: J.M.M. has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work. C.L. has received honoraria for speaking at educational events or consulting from BioNTech, Pfizer, Astra Zeneca, MSD, Novartis, Gilead, Janssen and ViiV. J.R. is an employee and stockholder of Gilead Sciences. A.M. has received honoraria, travel support and lecture fees from ViiV and Gilead, and honoraria from Eiland and Bonnin, all outside the submitted work. Publisher Copyright: © 2023 by the authors.

PY - 2023/7

Y1 - 2023/7

N2 - Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.

AB - Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.

KW - AIDS defining cancer

KW - body mass index

KW - HIV

KW - incidence

KW - infection

KW - non-AIDS defining cancer

KW - smoking

KW - trends

UR - http://www.scopus.com/inward/record.url?scp=85166264576&partnerID=8YFLogxK

U2 - 10.3390/cancers15143640

DO - 10.3390/cancers15143640

M3 - Article

C2 - 37509301

AN - SCOPUS:85166264576

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 14

M1 - 3640

ER -

Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this